Oncology

cancer target detection radiopharma radio
Biotech

Actuate's pancreatic cancer drug boosts survival by 3 months

Actuate has set its sights on getting elraglusib approved for pancreatic cancer after the GSK-3β drug showed a three-month survival increase.
James Waldron Jun 2, 2025 7:30am
abbvie

AbbVie taps oncology research org for aid running diverse trials

May 28, 2025 11:25am
graphic image of a cube with an arrow nailing the bullseye

ASCO: Cullinan drug sees 35% ORR in pretreated NSCLC

May 22, 2025 5:00pm
BioNTech

BioNTech makes £1B commitment to expand UK research, build HQ

May 20, 2025 11:15am
reshuffle pipeline target reorganize shift change

Recursion streamlines pipeline following merger with Exscientia

May 5, 2025 11:00am
Caribou antlers sitting on ground with mountains in background

Caribou cuts 32% of staff, further purges cell therapy pipeline

Apr 24, 2025 9:55pm
More News

Mosaic licenses 2 clinical stage tumor drugs from Otsuka's Astex

Apr 24, 2025 10:00am

Bayer boosts precision oncology efforts with multiyear AI deal

Apr 23, 2025 12:55pm

Tempus AI in line for $200M from AstraZeneca cancer model deal

Apr 23, 2025 9:01am

Boehringer slots synthetic lethal program into oncology pipeline

Apr 23, 2025 7:45am